CONSHOHOCKEN, Pa., May 28, 2025--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025.

Investors in Cencora, Inc. COR need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 17, 2025 $160 Call had some of the highest implied ...

Cencora reported first-quarter fiscal 2025 adjusted earnings per share of $3.73, which beat the Zacks Consensus Estimate of $3.50 by 6.6%. The bottom line also improved 13.7% year over year.

Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment point to continued demand for the healthcare supplies and niche specialty drugs Cencora ...

July 31 (Reuters) - U.S. drug distributor Cencora (COR.N), opens new tab said on Wednesday that additional data on patients, beyond what was initially identified, had been stolen in a cyberattack ...

May 7 (Reuters) - U.S. drug distributor Cencora (COR.N), opens new tab raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Cencora is a 'super cash cow' with high capital turnover and low margins, generating substantial free cash flow from its competitive advantages. COR's business model thrives on low-cost operations ...

Shares of Cencora (COR) have been strong performers lately, with the stock up 11.2% over the past month. The stock hit a new 52-week high of $309.35 in the previous session. Cencora has gained 35. ...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.